Related Experiment Video
Updated: Oct 16, 2025

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
Published on: February 23, 2024
Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go Beyond
Francesca De Felice1, Laura Vertechy2, Elena Giudice2
1Department of Radiotherapy, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Purpose:
A practice synthesis of available evidence-based medicine data in ovarian cancer (OC), aiming to provide directions for future research.
Materials And Methods:
We performed a systematic review. PubMed was searched for relevant OC trials between January 2000 and December 2019.
Results:
Out of 865 references screened, 199 trials were found eligible for inclusion. Most trials were multicenter (83.9%). There was a trend reduction in the number of patients enrolled/per study over the years. Studies testing targeted/biological therapies dominated the second decade (60 trials in 2010-2019 versus 2 trials in 2000-2009). The proportion of trials with positive survival and clinical outcomes significantly increased from 23.8% in early 2000s to 54.1% in the last 5 years. Trials with histology/molecular biomarker criteria were more likely to meet progression-free survival endpoint than those without these selection criteria (69.2% versus 32.6%).
Conclusion:
This systematic review suggests a trend of increased positive studies, mainly linked to precision medicine.
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Treatment Resistant Cancers
Preclinical Development: Overview
Cancer Survival Analysis
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...

